Role of endothelin in a rabbit model of acute myocardial infarction: Effects of receptor antagonists

Journal of Cardiovascular Pharmacology

Volumn 28, Issue 6, 1996, Pages 774-783

  Vitola, João V ^a   Forman, Mervyn B ^a   Holsinger, John P ^a   Kawana, Masatoshi ^a   Atkinson, James B ^a   Quertermous, Thomas ^a   Jackson, Edwin K ^b   Murray, John J ^a  

^a VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF PITTSBURGH   (United States)

Author keywords

Endothelin; Endothelin receptor antagonist; Hemodynamics; Infarct size; Myocardium; Reperfusion injury

Indexed keywords

ENDOTHELIN 1; ENDOTHELIN A RECEPTOR ANTAGONIST; FRI 139317; PDI 145065; UNCLASSIFIED DRUG;

ACUTE HEART INFARCTION; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIARRHYTHMIC ACTIVITY; ARRHYTHMOGENESIS; ARTICLE; CORONARY ARTERY BLOOD FLOW; CORONARY ARTERY CIRCUMFLEX BRANCH; CORONARY ARTERY OBSTRUCTION; DRUG RECEPTOR BINDING; HEART INFARCTION SIZE; HEART MUSCLE PERFUSION; HEART VENTRICLE ARRHYTHMIA; MALE; NONHUMAN; PRIORITY JOURNAL; PROTEIN LOCALIZATION; PROTEIN SYNTHESIS; RABBIT; SYSTEMIC VASCULAR RESISTANCE;

ANIMALS; AZEPINES; ENDOTHELIN-1; HEART; HEMODYNAMIC PROCESSES; INDOLES; MALE; MYOCARDIAL REPERFUSION INJURY; MYOCARDIUM; OLIGOPEPTIDES; RABBITS; RECEPTORS, ENDOTHELIN; RNA, MESSENGER;

EID: 0029801666     PISSN: 01602446     EISSN: None     Source Type: Journal    
DOI: 10.1097/00005344-199612000-00007     Document Type: Article

References (44)

1. Forman MB, Virmani R. Pathogenesis and modification of myocardial reperfusion injury. In: Gersh BJ, Rahimtoola SH, eds. Acute myocardial infarction. New York: Elsevier Science, 1991:329-70.
2. Yanagisawa M, Kurihara H, Kimura S, et al. A novel potent vasoconstrictor peptide produced by vascular endothelial cells. Nature 1988;322:411-5.
3. Kurihara H, Yamaoki K, Nagai R, et al. A potent vasoconstrictor associated with coronary vasospasm. Life Sci 1989;44:1937-43.
4. Velasco CE, Atkinson JB, Kondo T, Virmani R, Inagami T, Forman MB. Enhanced local endothelin release contributes to no-reflow phenomenon in the canine model [Abstract]. J Am Coll Cardiol 1991;17:305A.
5. Velasco CE, Jackson EK, Morrow JA, Vitola JV, Inagami T, Forman MB. Intravenous adenosine suppresses cardiac release of endothelin after myocardial ischaemia and reperfusion. Cardiovasc Res 1993;27:121-8.
6. Kloner RA, Ganote CE, Jennings RB. The "no-reflow" phenomenon after temporary occlusion in the dog. J Clin Invest 1978;54: 1496-508.
7. Forman MB, Bingham S, Kopelman HA, et al. Reduction of infarct size with intracoronary perfluorochemical in a canine preparation of reperfusion. Circulation 1985;71:1060-8.
8. Olafsson B, Forman MB, Puett DW, et al. Reduction of reperfusion injury in the canine preparation by intracoronary adenosine: importance of the endothelium and the "no reflow phenomenon." Circulation 1987;76:1135-45.
9. Schvartz I, Itoop O, Hazum E. Direct evidence for multiple endothelin receptors. Biochemistry 1991;30:5325-7.
10. Ogawa Y, Nakao K, Arai H, et al. Molecular cloning of a nonisopeptide-selective human endothelin receptor. Biochem Biophys Res Commun 1991;178:248-55.
11. Heymann MA, Payne BD, Hoffman JIE, Rudolph AM. Blood flow measurements with radionuclide-labeled particles. Prog Cardiovasc Dis 1977;20:55-79.
12. Sambrook J, Fritsch EF, Maniatis T. Molecular cloning: a laboratory manual. 2nd ed. Cold Spring Harbor, NY: Cold Spring Harbor Laboratory, 1989.
13. Chirgwin JM, Przybyla AE, MacDonald RJ, Rutter WJ. Isolation of biologically active ribonucleic acid from sources enriched in ribonuclease. Biochemistry 1979;18:5296-9.
14. Lee ME, Temizer DH, Clifford JA, Quertermous T. Cloning of the GATA-binding protein that regulates endothelin-1 gene expression in endothelial cells. J Biol Chem 1991;266:16188-92.
15. B receptor antagonist (PD 145065) and related analogues. Med Chem Res 1993;3:156-62.
16. Doherty AM, Cody WL, He JX, et al. In vitro and in vivo studies with a series of hexapeptide endothelin antagonists. J Cardiovasc Pharmacol 1993;22(suppl 8):S98-102.
17. Faria DB, Cheung WM, Ribeiro LGT, Maroko PR. Effects of lidocaine and droxicainide on myocardial necrosis: a comparative study. J Am Coll Cardiol 1983;1:1447-52.
18. Lesnefsky EJ, VanBenthuysen KM, McMurtry IF, Shikes RH, Johnston RB Jr, Horwitz LD. Lidocaine reduces canine infarct size and decreases release of a lipid peroxidation product. J Cardiovasc Pharmacol 1989;13:895-901.
19. Vitola JV, Forman MB, Holsinger JP, Atkinson JB, Murray JJ. Reduction of myocardial infarct size in rabbits and inhibition of activation of rabbit and human neutrophils by lidocaine. Am Heart J 1997 (in press).
20. Norton ED, Jackson EK, Virmani R, Forman MB. Effects of intravenous adenosine on myocardial reperfusion injury in a model with low myocardial collateral blood flow. Am Heart J 1991;122:1283-91.
21. Zar JH. Comparing simple linear regression equations. In: Biostatistical analysis. Englewood Cliffs, NJ: Prentice Hall, 1984:292-8.
22. Maxwell M, Hearse D, Yellow D. Species variation in the coronary collateral circulation during regional myocardial ischemia: a critical determinant of the rate of evolution and extent of myocardial infarction. Cardiovasc Res 1987;21:737-46.
23. Levin ER. Endothelins. N Engl J Med 1995;333:356-63.
24. Pernow J, Wang QD, Li XS, Lundberg JM. Reduced infarct size and improved myocardial blood flow following ischemia and reperfusion by a non-peptide endothelin receptor antagonist [Abstract]. J Am Coll Cardiol 1995;25(suppl):58A.
25. Battistini B, D'Orleans-Juste P, Sirois P. Endothelins: circulating plasma levels and presence in other biologic fluids. Lab Invest 1993;68:600-28.
26. Tønnessen T, Giaid A, Naess PA, Yanagisawa M, Christensen G. Endothelin-1 is synthesized and produced by ischemic cardiomyocytes in vivo [Abstract]. Circulation 1994;90(suppl):1-426.
27. McMurdo L, Thiemermann C, Vane JR. The effects of the endothelin ETA receptor antagonist, FR139317, on infarct size in a rabbit model of acute myocardial ischaemia and reperfusion. Br J Pharmacol 1994;112:75-80.
28. B) mediate vasoconstriction in the perfused rat heart. J Cardiovasc Pharmacol 1993;22(suppl 8):S246-51.
29. Watanabe T, Suzuki N, Shinamoto N, Fujino M, Imada A. Contribution of endogenous endothelin to the extension of myocardial infarct size in rats. Circ Res 1991;69:370-7.
30. Kusumoto K., Awane Y, Fujiwara S, Watanabe T. Role of endogenous endothelin in extension of rabbit myocardial infarction. J Cardiovasc Pharmacol 1993;22(suppl 8):S339-42.
31. B receptor antagonist, TAK-044 and the inhibition of myocardial infarct size in rats. Br J Pharmacol 1995;114: 949-54.
32. Grover GJ, Dzwonczyk S, Parham CS. The endothelin-1 receptor antagonist BQ123 reduces infarct size in a canine model of coronary occlusion and reperfusion. Cardiovasc Res 1993;27:1613-8.
33. Han H, Neubauer S, Braeker B, Ertl G. Endothelin-1 contributes to ischemia/reperfusion injury in isolated rat heart - attenuation of ischemic injury by the endothelin-1 antagonist BQ123 and BQ610. J Mol Cell Cardiol 1995;27:761-6.
34. Velasco CE, Yanagisawa M. Endothelins protect the ischemic myocardium [Abstract]. J Am Coll Cardiol 1994;23(suppl):30A.
35. Velasco CE, Yanagisawa M, Williamson JL, Triana JF. Cardioprotective action of endothelin-1 during ischemia [Abstract]. Circulation 1993;88:I-544.
36. Badr KF, Murray JJ, Breyer MD, Takahashi K, Inagami T, Harris RC. Mesangial cell, glomerular and renal vascular responses to endothelin in the rat kidney: elucidation of signal transduction pathways. J Clin Invest 1989;83:336-42.
37. Klemm P, Warner TD, Hohlfeld T, Corder R, Vane JR. Endothelin-1 mediates ex vivo coronary vasoconstriction caused by exogenous and endogenous cytokines. Proc Natl Acad Sci USA 1995;92: 2691-5.
38. Davies MG, Hagen PO. The vascular endothelium: a new horizon. Ann Surg 1993;218:593-609.
39. Yorikane R, Koike H, Miyake S. Electrophysiological effects of endothelin-1 on canine myocardial cells. J Cardiovasc Pharmacol 1991;17(suppl 7):S159-62.
40. Salvati P, Chierchia S, Dho L, et al. Proarrhythmic activity of intracoronary endothelin in dogs: relation to the site of administration and to changes in regional flow. J Cardiovasc Pharmacol 1991;17:1007-14.
41. Tomoda H. Plasma endothelin-1 in acute myocardial infarction with heart failure. Am Heart J 1993;123:667-72.
42. Tomoda H. Coronary thrombolysis and endothelin-1 release. Angiology 1993;44(6):441-6.
43. Omland T, Lie RR, Aakvaag A, Aarsland T, Dickstein K. Plasma endothelin determination as a prognostic indicator of 1 year mortality after acute myocardial infarction. Circulation 1994;89:1573-9.
44. Galatius-Jensen S, Wroblewski H, Emmeluth C, Bie P, Haunso S, Kastrup J. Plasma endothelin-1 in chronic heart failure: a predictor of cardiac death [Abstract]? Circulation 1994;90(suppl):I-379.